Infliximab API is a pharmaceutical-grade chimeric monoclonal antibody that specifically binds to Tumor Necrosis Factor-alpha (TNF-α), a key cytokine involved in chronic inflammatory and autoimmune diseases. By neutralizing TNF-α activity, Infliximab reduces inflammation, tissue damage, and immune-mediated disease progression.
Infliximab is indicated for the treatment of Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis, and Plaque Psoriasis. It is formulated as an intravenous injectable biologic and is widely used in advanced immunotherapy.
Manufactured under WHO-GMP-certified biopharmaceutical facilities, our Infliximab API is produced using advanced recombinant biotechnology processes to ensure exceptional purity, biological activity, stability, and batch-to-batch consistency. Every batch undergoes stringent quality testing and is supplied with complete documentation including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications.
Infliximab API is used in injectable biopharmaceutical formulations for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
Infliximab binds specifically to TNF-α, blocking its inflammatory activity and reducing immune-mediated tissue damage associated with autoimmune disorders.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Infliximab API in commercial quantities for pharmaceutical and biopharmaceutical manufacturing with worldwide export support.
Get Bulk Quote via WhatsApp